Guardant Health PE Ratio 2017-2022 | GH

Current and historical p/e ratio for Guardant Health (GH) from 2017 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Guardant Health PE ratio as of February 03, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Guardant Health PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-02-03 31.94 0.00
2022-09-30 53.83 $-5.93 0.00
2022-06-30 40.34 $-5.41 0.00
2022-03-31 66.24 $-4.12 0.00
2021-12-31 100.02 $-4.00 0.00
2021-09-30 125.01 $-4.05 0.00
2021-06-30 124.19 $-3.77 0.00
2021-03-31 152.65 $-3.38 0.00
2020-12-31 128.88 $-2.58 0.00
2020-09-30 111.78 $-1.91 0.00
2020-06-30 81.13 $-1.27 0.00
2020-03-31 69.60 $-0.83 0.00
2019-12-31 78.14 $-0.84 0.00
2019-09-30 63.83 $-0.87 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.272B $0.374B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00